ZD1839 (IRESSA™) in combination with docetaxel & cisplatin in subjects with metastatic head & neck cancer

Study identifier:1839IL/0504

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase II study to evaluate the safety and efficacy of the combination of ZD1839 (IRESSA™), docetaxel and cisplatin in subjects with recurrent and/or metastatic head and neck cancer

Medical condition

head and neck cancer

Phase

Phase 2

Healthy volunteers

No

Study drug

ZD1839 (IRESSA™), Docetaxel, Cisplatin

Sex

All

Actual Enrollment

36

Study type

Interventional

Age

18 Years - 70 Years

Date

Study Start Date: 01 Jul 2003
Primary Completion Date: 01 Mar 2006
Study Completion Date: 01 Mar 2006

Study design

Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria